Staphylococcus aureus is a major cause of infectious disease in the United States and in the world. S. aureus can infect almost every human tissue, causing pathologies ranging from minor skin infections to rapidly life- threatening infections, such as necrotizing pneumonia and sepsis. Treatment options for S. aureus infection are dwindling as multidrug resistant strains continue to emerge and to become more common both inside and outside of the hospital. S. aureus has many virulence factors that it uses to evade host immunity and be so successful as a pathogen. One class of these virulence factors is the bi-component pore-forming leukotoxins. These toxins kill host cells by binding to specific protein receptors and forming pores in their cell membranes, lysing the cells. The leukotoxins kill neutrophils, which are key mediators of immunity to acute bacterial infection, and thus help the bacteria to survive during infection. Two of these toxins, LukED and HlgAB, are also capable of killing red blood cells, and recent work has shown that this is accomplished by targeting the DARC receptor. Interestingly, both of these toxins are lethal to mice when administered intravenously. We now aim to investigate the role of the DARC receptor in the activity of these toxins and in S. aureus pathogenesis more fully by pursuing the following aims: (1) Define the mechanism(s) by which LukED and HlgAB are lethal in vivo and the role of DARC and (2) Determine the molecular mechanism by which these toxins target DARC. Together, these studies will advance our understanding of S. aureus pathogenesis and highlight the need to develop novel therapies and vaccines that inhibit the actions of these toxins.

Public Health Relevance

S. aureus bi-component pore forming leukotoxins cause rapid death upon injection into mice. Elucidating the mechanism of this phenotype will improve our understanding of the pathogenesis of deadly diseases caused by this bacteria such as sepsis and necrotizing pneumonia and help the guide the development of new therapeutic modalities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA) (F30)
Project #
1F30AI124606-01
Application #
9121734
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Huntley, Clayton C
Project Start
2016-04-01
Project End
2019-11-30
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
New York University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Blake, Kimbria J; Baral, Pankaj; Voisin, Tiphaine et al. (2018) Staphylococcus aureus produces pain through pore-forming toxins and neuronal TRPV1 that is silenced by QX-314. Nat Commun 9:37
Lubkin, Ashira; Torres, Victor J (2017) Bacteria and endothelial cells: a toxic relationship. Curr Opin Microbiol 35:58-63
Reyes-Robles, Tamara; Lubkin, Ashira; Alonzo 3rd, Francis et al. (2016) Exploiting dominant-negative toxins to combat Staphylococcus aureus pathogenesis. EMBO Rep 17:428-40
Lubkin, Ashira; Torres, Victor J (2015) The ever-emerging complexity of ?-toxin's interaction with host cells. Proc Natl Acad Sci U S A 112:14123-4